Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World August 3, 2006 Katharine Sanderson	New Drug Joins the Anti-HIV Armoury A treatment for drug-resistant HIV has been approved for use in the US. The milestone will lead to mass-produced treatments for other drug-resistant viruses in the developing world, its creators claim.
BusinessWeek September 12, 2005 John Carey	A Better Way To Ambush AIDS? HIV increasingly outwits today's drugs even as side effects take a toll. But Panacos Pharmaceuticals' experimental drug opens the door to a new line of attack.
The Motley Fool July 13, 2004 Charly Travers	With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market.
Pharmaceutical Executive December 1, 2005 Alana Klein	Thought Leader: A Q&A with Graham Allaway While researchers continue to hunt for new AIDS drugs, Graham Allaway, chief operating officer of Panacos Pharmaceuticals, is focusing on developing a treatment for patients failing therapy due to resistance.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
Bio-IT World June 2006 Steven Withrow	SUNY-SGI Collaboration Yields AIDS Breakthrough Working on an SGI Altix system located at the National Center for Supercomputing Applications, researchers recently modeled how HIV protease works across time, which the team hopes will lead to more targeted medicines to interfere with virus development.
The Motley Fool June 21, 2011 Frank Vinluan	GSK HIV Drug Pipeline Sees Boost as Partner Concert Steers to Clinical Trials GSK and Concert have a possible new treatment for HIV.
Chemistry World May 2, 2008 Richard Van Noorden	Synthesis boost for HIV research Hopes for a new type of HIV therapy have been raised by the first chemical synthesis of a scarce plant compound which flushes the virus out of hiding.
Chemistry World January 6, 2011 Laura Howes	Using HIV against itself US researchers have developed a 'Trojan horse' molecule that uses HIV to trigger the release of a drug that destroys the virus.
The Motley Fool April 3, 2008 Brian Lawler	A Punch to Gilead's Competition A rival compound's bad data signals a better future for Gilead's lead drugs.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	HIV: Better Combos and Classes Keep Coming The new class of integrase inhibitors is the main event on the calendar, as Gilead's elvitegravir and ViiV Healthcare's GSK 1349572 come online in 2013 and 2014, respectively.
Chemistry World June 21, 2007 Simon Hadlington	Boron is Key to Antifungal Agent Researchers have shown that the presence of a boron atom is key to an antifungal agent being developed to treat infections of fingernails and toenails.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Hepatitis C: Another Protease Revolution The launch of a new class of protease inhibitors is set to transform HCV treatment over the next decade, with kinder, gentler oral antiviral cocktails that will increase success rates from 50 percent to 75 percent.
Salon.com July 17, 2000 Nina Teicholz	When drugs take a holiday Could taking a break from protease inhibitors be the secret to treating AIDS? A new case of a 40-year-old man in Philadelphia shows it's possible.
Chemistry World September 9, 2007 Simon Hadlington	Sugaring the Pill Researchers in the US have made a key advance in efforts to bolt sugar molecules onto natural products in the search for new drugs.
BusinessWeek November 24, 2003 John Carey	Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells.
The Motley Fool November 8, 2007 Brian Lawler	Idenix Reels Itself In The small-cap drug developer cuts expenditures in the third quarter when sales of their hepatitis treatment don't materialize as quickly as hoped. Investors, take note.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
IEEE Spectrum February 2009 Monica Heger	Computer-Designed Drugs Could Thwart Antibiotic-Resistant Bacteria Researchers use computer algorithms to tweak enzymes that make antibiotics
Chemistry World December 13, 2007 Lewis Brindley	Semen Protein Raises HIV Infection Risk Scientists have identified a protein in human semen that increases the risk of HIV infection up to 100,000 fold. The discovery could provide new drug targets and strategies for combating the global AIDS epidemic.
Chemistry World July 23, 2007 Michael Gross	Goat Antidote An enzyme known to act as a powerful antidote against organophosporous compounds has been expressed in the milk of transgenic goats, report researchers Organophosphorus compounds are recognized as potential chemical weapons agents.
The Motley Fool October 19, 2007 Brian Lawler	Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down.
Chemistry World March 2011	60 years of innovation To celebrate the international year of chemistry, James Mitchell Crow looks back at some of the discoveries and developments made by chemists over the past six decades
The Motley Fool October 16, 2007 Brian Orelli	Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note.
Chemistry World November 6, 2009 Phillip Broadwith	Enzyme binds both sides of the mirror European chemists have discovered that both mirror-image forms of a particular compound can bind at the same time in the same site of an enzyme, a phenomenon that has never been seen before.
Scientific American October 2008 John Rennie	Hope and the Fight against HIV The battle must continue, even if 25 years of research have disappointed.
The Motley Fool June 26, 2008 Brian Lawler	Ardea Takes the More Exciting Route Ardea Bioscicences announces phase 2a data for its lead anti-HIV drug that is good enough to encourage further testing.
Popular Mechanics December 1, 2006 Ben Harder	Fighting HIV by Building a New Killer In the fight to find a cure for AIDS, researchers have invented a viral double agent on a mission to seek out where HIV hides.
Chemistry World August 4, 2008 Pete Mitchell	Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate.
BusinessWeek September 2, 2010 Simeon Bennett	David Margolis' Fight to End AIDS The North Carolina professor is relying on Zolinza, a rarely used Merck cancer drug, to stamp out AIDS.
Salon.com October 12, 2000 Katharine Mieszkowski	Your computer can fight AIDS A PC can do more in its spare time than look for aliens. It can also save lives. Even while you're reading this Web page, you could be researching new AIDS treatments, or rather, your computer could...
Pharmaceutical Executive July 30, 2007 Walter Armstrong	Tibotec Gets AIDS With a new wave of "resistant to resistance" HIV drugs, a record of consistent innovation, and a dynamic partnership with AIDS activists, Tibotec is in it to win it. And end it.
The Motley Fool April 24, 2007 Brian Lawler	Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes.
Chemistry World April 27, 2007 Ned Stafford	New HIV Blocker Prepares for Trials Scientists who isolated a natural component of human blood that defends against the HIV-1 virus are now moving quickly to test their ideas clinically in the hope of bringing a new class of HIV-blockers based on peptide therapeutics to market.
Chemistry World October 2008 Derek Lowe	Column: In the pipeline The author seeks a cure for 'compound bloat'
Chemistry World September 7, 2014 Michael Gross	Bringing chemical synthesis to the masses The promise of a novel approach to building chemical libraries, which only requires simple building blocks in water, without any additional reagents or sample preparation, is inspired by nature.
Chemistry World April 21, 2010 Sarah Houlton	Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials.
Chemistry World March 10, 2008 Victoria Gill	New Hope for Anti-HIV Gels Early data from a clinical trial has rekindled hope of an effective topical gel to prevent HIV infection.
Chemistry World January 17, 2010 Simon Hadlington	Sugars synthesised with help of promiscuous enzyme European researchers have discovered a new way to make synthetically elusive sugar molecules that could lead to novel vaccine candidates and other medically important compounds.
Nursing August 2008 Carl A. Kirton	Managing Long-Term Complications of HIV Infection Now that advances in treatment have transformed HIV into a chronic, manageable disease, patients are facing cardiovascular and metabolic complications you might not have expected 15 years ago. Here's how to help your patient manage them.
Chemistry World January 19, 2007 Lionel Milgrom	Quantum Theory Reveals Why Lead Poisons Lead is one heavy metal. It can cause irreversible blood, brain, kidney, and liver damage. But why is it so toxic? Using quantum chemistry and enzyme model compounds, researchers now believe they have the answer.
Chemistry World July 8, 2010 Sarah Houlton	Antibodies spark HIV vaccine hopes These cross-reactive broadly neutralising antibodies bound to and neutralised more than 90 per cent of the HIV strains they were tested against.
Chemistry World August 13, 2009 Simon Hadlington	Forcing enzyme activity New research has shown that physically stretching an enzyme can trigger its activity - even when the active site is not hidden in a 'cryptic' position. Mechanical force may play a more important role in biological molecular systems than previously realized.
Chemistry World January 7, 2014 Derek Lowe	Is there a drug for that? One hears a lot about the concept of 'druggability' in pharmaceutical research. If that concept has any meaning (and it probably does), then the implication is that there must be such a thing as 'undruggability'. So what does that look like?
Chemistry World July 11, 2012	Gsk Drug Shines in HIV Trial GlaxoSmithKline has announced good results for its HIV - Aids drug candidate dolutegravir, which has apparently outperformed Atripla tablets in Phase III.
American Journal of Nursing March 2010 Bradley-Springer et al.	Every Nurse Is an HIV Nurse The evolution of HIV infection into a chronic disease has implications across all clinical care settings. Every nurse should be knowledgeable about the disease in order to provide high-quality care to people with or at risk for HIV.
Pharmaceutical Executive October 1, 2008	The other half of an HIV mystery is solved When HIV infects a human immune cell, which of the cell's own genes play a role?
The Motley Fool September 25, 2007 Brian Orelli	Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note.
The Motley Fool October 31, 2007 Brian Lawler	The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note.
American Family Physician July 15, 2004	HIV Infection - How to Lower Your Risk A consumer-oriented brochure discussing the many ways to lower the risk of getting human immunodeficiency virus (HIV) infection and where to go for help.